Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07130903 · ClinicalTrials.gov registry record · Phase 2
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Adenocarcinoma, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 9
- Study locations
NCT07130903: Recruiting Phase 2 study of Metastatic Colorectal Adenocarcinoma, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT07130903 is a Phase 2 study of Metastatic Colorectal Adenocarcinoma that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 102 participants, above the 81-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (26% higher). The trial reports 9 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07130903, a Phase 2 study of Metastatic Colorectal Adenocarcinoma, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable
Primary Outcome
Overall survival (OS) is defined as the time duration from treatment start until death of any cause. The distribution of OS will be graphically summarized by a Kaplan-Meier (KM) curve, and median OS (mOS) and its one-sided 85% (i.e., two-sided 70%) confidence interval (CI) will be estimated using KM estimates.
Conditions Studied
Interventions
- DRUG Fruquintinib
- DEVICE TheraBionic P1
Study Locations (9)
Michigan
- Karmanos Cancer Institute at McLaren Bay Region - Bay City
- Karmanos Cancer Institute at McLaren Clarkston - Clarkston
- Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute at McLaren Flint - Flint
- Karmanos Cancer Institute at McLaren Greater Lansing - Lansing
- Karmanos Cancer Institute at McLaren Lapeer Region - Lapeer
- Karmanos Cancer Institute at McLaren Macomb - Macomb
- Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey - Petoskey
- Karmanos Cancer Institute at McLaren Port Huron - Port Huron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2030-04-17 |
| Phase | Phase 2 |
What NCT07130903 shows while recruiting
NCT07130903 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (26% higher).
The record links to 1 condition, with Metastatic Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Fruquintinib is the first listed.
NCT07130903 lists 9 locations in 1 state (Michigan).
Frequently Asked Questions
What is clinical trial NCT07130903 about?
NCT07130903 is a clinical study titled "Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer". The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable
What is the current status of trial NCT07130903?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2025-09-10. Estimated completion is 2030-04-17.
What conditions does trial NCT07130903 study?
This clinical trial studies the following conditions: Metastatic Colorectal Adenocarcinoma.
What interventions are being tested in trial NCT07130903?
The interventions under investigation include: Fruquintinib (DRUG), TheraBionic P1 (DEVICE).
Who is sponsoring clinical trial NCT07130903?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07130903 being conducted?
This trial has 9 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07130903's enrollment target sits among peer trials
102 5th of 14 higher than 10 of 14 other Metastatic Colorectal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
COMPLETED · Phase 2
-
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
RECRUITING · Phase 1
-
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI